NovaBiotics has unique patented anti-infectives

NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat, poorly served infectious conditions.

NovaBiotics has looked to nature as the template for engineering a totally novel class of antimicrobial peptide therapies and believes its patented, proprietary technology has potential to meet the need for safer, more effective antimicrobials and address the various and well described shortcomings of conventional anti-infective therapies.  Its rational drug design approach and unique patented peptide anti-infective technology has already been validated through successful clinical development of the company’s lead compound, Novexatin®, a topical (brush on) treatment for fungal nail infections. A robust and exciting pipeline of drug candidates are also being developed for conditions such as life threatening blood stream fungal infections (predominantly candidaemia) and cystic fibrosis.


1 thought on “NovaBiotics has unique patented anti-infectives

  1. Bill Henderson Post author

    NovaBiotics has first-in-class therapeutic solutions to antibiotic and antifungal drug resistance and the rise of emerging pathogens in a number of complex, medically unmet infectious conditions.

    A global approach is tackling the need for new anti-infective therapies and the challenges of antimicrobial resistance (AMR). “Real life” infections involve complex polymicrobial biofilms. NovaBiotics has developed not just antibacterial therapies, but also antifungal therapies, antibiofilm agents and resistance-breaking technology that can be used alongside antibacterial therapies to extend and expand the lifespan and utility of existing antibiotics.

Leave a Reply